Lancet: weekly semaglutide cuts heavy drinking days 41% in AUD trial

The Lancet published the full Phase III results of an international RCT testing once-weekly semaglutide for alcohol use disorder, led by Dr. Anders Fink-Jensen at Copenhagen University Hospital with NIH collaboration. The trial enrolled 108 adults with both AUD (AUDIT score >15, ≥6 heavy drinking days per month) and obesity (BMI ≥30). Both arms received CBT focused on motivation, craving, and relapse prevention.

What the trial found

The semaglutide arm — titrated to 2.4 mg weekly over 26 weeks — recorded a 41.1% reduction in heavy drinking days, a 13.7 percentage point improvement over the placebo arm. The number needed to treat was 4.3, meaning fewer than five patients had to be treated for one to benefit — a better NNT than any FDA-approved AUD medication (naltrexone, acamprosate, disulfiram), which sit at NNT ≥7. Adverse effects were mild and transient: gastrointestinal symptoms typical of GLP-1 agonist titration.

What the trial does not yet show

This is a single Phase III result in a specific population (AUD + obesity). The mechanism is plausible — GLP-1 receptor signaling intersects with reward circuitry — but generalizing to non-obese AUD populations requires the follow-up trials already underway. Semaglutide is not yet FDA-approved for AUD; off-label prescribing patterns are likely to outpace evidence, as has happened with ketamine clinics. Treatment teams should expect questions from patients and prepare a clinical framework that pairs any GLP-1 trial with continued evidence-based behavioral therapy.

Why this matters for people in recovery

For an estimated 28 million U.S. adults living with AUD, the pharmacotherapy bench has been thin and adherence has been a chronic problem. A once-weekly injection, even before FDA labeling, gives clinicians a new conversation to have with patients who have not responded to oral medications. If you’re considering medication-assisted treatment for alcohol use, explore Rize’s alcohol pathway and talk to a treatment-matching specialist.

Crisis line: SAMHSA 1-800-662-HELP (4357).

— The Rize Recovery Newsroom